Core Viewpoint - The article discusses the safety of GLP-1 receptor agonists (GLP-1RAs), particularly regarding their potential link to thyroid cancer, based on a recent large-scale study that provides reassuring evidence for patients and healthcare providers [1][2][3]. Group 1: Background on GLP-1RAs - GLP-1 receptor agonists, such as semaglutide and liraglutide, are gaining attention for their dual benefits of lowering blood sugar and aiding weight loss among diabetes and obesity patients [1]. - Concerns have been raised about the potential risk of thyroid cancer associated with these medications, leading to confusion among doctors and patients [2][6]. Group 2: Research Findings - A significant study published in June 2025 in the journal "Diabetes Care" analyzed data from over 460,000 type 2 diabetes patients who were first-time users of GLP-1RAs, comparing them with patients using other common second-line diabetes medications [3][7]. - The study employed rigorous methodologies, including adjustments for 90,000 variables and a one-year delay analysis to enhance the reliability of the results [7]. Group 3: Results and Implications - The study found no significant increase in thyroid cancer risk among GLP-1RA users compared to those on other medications, with the risk ratio close to 1 and not statistically significant [8]. - The incidence rate of thyroid cancer in the GLP-1RA group was approximately 0.88 to 1.03 per 1,000 person-years, comparable to the control group, indicating no elevated risk [8]. Group 4: Recommendations - The findings suggest that patients currently using or considering GLP-1RAs can be reassured about the thyroid safety of these medications [9]. - While the study has limitations, such as the exclusion of some European data and the retrospective nature of the analysis, it remains one of the most comprehensive studies on this topic to date [10][12]. Group 5: Conclusion - The research serves as an important reference for healthcare providers in making medication decisions and alleviating patient concerns regarding cancer risks associated with GLP-1RAs [11]. - Ongoing accumulation of long-term data will further enhance understanding of the safety profile of these drugs [12].

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity crisis and the necessity for innovative solutions that integrate technology, policy, and community efforts [3][5][18]. Group 1: Obesity Crisis and Health Implications - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [3]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, while youth rates may hit 31.8% [3]. - Obesity is linked to over 200 diseases, leading to annual medical expenditures exceeding 240 billion yuan [5]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes a dual focus on muscle gain and fat loss, moving away from the sole reliance on BMI for health assessments [6]. - Innovative products, such as a patented CLA+ whey protein blend, have shown promising results in trials, with users gaining an average of 2.3 kg of muscle and losing 4.7 kg of fat over three months [6]. - The "Metabolic Map" project aims to utilize wearable devices to monitor metabolic health indicators, enhancing personalized health management [7]. Group 3: New Approaches to Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks to address obesity linked to microbiome imbalances [8]. - A combination of prebiotics and postbiotics has been developed to promote beneficial gut bacteria, resulting in users experiencing a 5 cm reduction in waist circumference and a 23% improvement in skin elasticity [8]. - The integration of skin-tightening treatments in weight loss programs is gaining traction, with high satisfaction rates reported post-treatment [9]. Group 4: Addressing Market Challenges - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [12]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals adhering to obesity treatment guidelines and a shortage of specialized medical professionals [13]. Group 5: Future of Weight Management - The future of weight management is expected to leverage advanced technologies such as AR body fat scanning and AI-driven personalized plans, making weight loss more intelligent and effective [17]. - A collaborative approach involving government, businesses, and communities is essential to create a supportive environment for health initiatives [17].

整理 | GLP1减重宝典内容团队 尽管财务细节尚未公开，协议包括一笔未披露的首付款、股权投资以及基于阶段性成果的激励。根据协议内容，礼来将获得对Juvena研发出的 领先候选药物的独家开发权；若项目进入后期阶段，礼来将主导其研究、开发与商业化进程。 在刚刚宣布合作开发长效GLP-1受体激动剂后，礼来（Eli Lilly）又达成了一项新的生物技术合作协议，进一步拓展其在减重治疗领域的影响 力。此次，这家制药巨头与Juvena Therapeutics携手，拟通过高达6.5亿美元的里程碑支付，共同开发有助于维持肌肉质量与功能的新疗法。 这是礼来在一周内签署的第二份重要合作协议。此前，公司刚与瑞典企业Camurus达成合作，最高承诺金额达8.7亿美元，其中包括2.9亿美元的 预付款。该协议赋予礼来使用Camurus专有长效药物递送技术的权利，以开发长效版本的GLP-1及其他促胰素类候选药物。 通过此次与Juvena的合作，礼来将接入其AI驱动的JuvNET筛选平台。该平台可映射由再生干细胞分泌的蛋白质的治疗潜力，用于发现能改善肌 肉健康与身体成分的新型药物候选分子——这在减重治疗中尤为关键。 目前尚不清楚此次合作 ...

整理 | GLP1减重宝典内容团队 Johann Hari写了一本名为《神奇药物》（Magic Pill）的新书。他是一名住在伦敦和拉斯维加斯的记者。 你最担心的潜在风险是什么？ 司美格鲁肽用于肥胖患者只有两年多一点的时间。我们不知道服用它们的长期影响。有人担心它们可能会产生一些我们不知道的长期影响。 具体是什么让你烦恼？ 2023 年，Hari 体重 203 磅（180斤），体脂率为 32%，医生给他开了这种药来减肥。 Hari 的祖父 44 岁时死于心脏病，他的叔叔 60 多岁，他的父亲 70 多岁时接受了四次心脏搭桥手术。Hari 没有糖尿病，他对减肥药持谨慎态 度，因为他知道过去的选择"总是以灾难告终"，他说。但使用 Ozempic 减肥似乎是降低自身心脏病风险的一种方法。 第一次服药几天后，他就注意到了这种药物的效果。"我醒来后想，'有点奇怪。那是什么？'我不知道那是什么。然后我突然意识到我醒了，但 我不饿。我以前从来没有发生过这种事。从那时起，我的食欲就急剧下降。我比以前饿得多。我很快就感到很饱。" 哈里最终通过服用 Ozempic 和Wegovy 减掉了 42 磅（38斤）。在他的新书《神奇药物 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 在今年全国两会上，国家卫生健康委主任雷海潮用7分钟时间详细介绍了"体重管理年"三年行动计划，旨在推动全社会树立体重管理意识，养成健康饮 食和积极锻炼的良好生活方式，真正实现全民重视体重、科学管理体重的目标。 ▍普通人：管住嘴，迈开腿，养成好习惯 《中国居民营养与慢性病状况报告（2020年）》数据显示，2018年我国成年人的超重率为34.3%，肥胖率为16.4%。国家卫生健康委近日发布的《体重 管理指导原则（2024年版）》也提到，相关研究预测，如果不加以有效控制，到2030年我国成人超重和肥胖率将升至70.5%，儿童超重和肥胖率也可能 达到31.8%。 对普通人来说，管理体重其实并不复杂，关键在于坚持做好日常生活中的细节，同时也可以寻求专业医疗机构的帮助和建议。 首先，合理控制每日热量摄入非常重要。可以根据自己的年龄、性别和日常活动量，初步估算出所需的热量，然后有针对性地安排饮食结构。 需要注意的是，控制热量并不等同于盲目节食，而是要保证营养全面均衡。 ...

此次交易赋予诺和诺德在全球范围内获得Deep Apple小分子候选药物的许可权，这些药物面向一个尚未公开的、非促胰素GPCR靶点，具备治 疗肥胖和其他心代谢疾病的潜力。尽管具体靶点尚未披露，Deep Apple表示，其管线中有三个肥胖项目，其中两个不依赖GLP-1途径，显示出 差异化的研发方向。 根据协议，Deep Apple将负责候选化合物的发现和优化工作，诺和诺德则会参与早期研究计划，并在启动临床前IND研究之前接手全部开发工 作。这一合作模式与诺和诺德近期的策略相一致：通过获取早期、机制差异化的资产，强化其长期创新能力。 本次合作是在诺和诺德下一代肥胖候选药物CagriSema在三期临床试验中未达预期之后达成的。尽管该药显示出一定的减重效果，但结果未达 到公司内部目标，令竞争对手礼来凭借替尔泊肽（tirzepatide）进一步稳固了在当前肥胖药物市场的领先地位。 整理 | GLP1减重宝典内容团队 诺和诺德正进一步巩固其在快速增长的肥胖治疗市场中的领先地位，近日宣布与Deep Apple Therapeutics达成一项最高价值达8.12亿美元的合 作协议，获取针对非促胰素类GPCR靶点的小分子药物。这 ...

大家应该都听说了，国家正在大力推进"体重管理年"的相关举措吧？没错，如今国家正式发出号召，动员大家一起减肥。而且，这不仅仅是今 年的行动，未来很可能会持续成为每年的重点任务。 就在最近召开的全国两会上，国家卫生健康委员会主任雷海潮表示，今后将持续推动"体重管理年"相关工作。实际上，从2024年6月起，国家 卫健委就已经联合教育部、体育总局等多个部门，正式启动了为期三年的"体重管理年"专项行动。 去年年底，一场以体重管理年为主题的交流会上，国家心血管病中心健康生活方式医学中心常务副主任冯雪老师还特别指出，医生应该积极投 身健康科普，人人都要用写论文的劲头来普及健康知识，形成全民参与的科普合力。 说到底，减肥早已不仅仅是个人的事，现在已经上升为全社会的共同课题。查阅相关资料你会发现，肥胖问题影响深远。对个人来说，肥胖是 健康和身材的挑战；但当肥胖成为群体性问题时，甚至会对整个宏观经济产生影响。 别小看了这句话，这绝不是危言耸听。 ▍为什么说肥胖会影响宏观经济？ 什么是肥胖？目前国际通用的衡量标准主要有体脂率、腰围、腰臀比等，但最常见的还是体质指数（BMI）。BMI的计算方法是用体重（公 斤）除以身高（米）的平方。 ...

整理 | GLP1减重宝典内容团队 替尔泊肽的半衰期为 5 天。如果停止使用替尔泊肽，药物需要大约 30 天才能从您的体内排出。使用替尔泊肽并不能保证每周减掉一定量的体 重。但是， 专家建议每周减掉 1 到 2 斤是安全的减重速度 。 健康减肥需要时间。根据SURMOUNT-1试验，在开始使用替尔泊肽后的最初几周内，效果可能不明显。药物在第一次使用后开始起效，但减肥 效果不会立竿见影。 使用替尔泊肽的前四周内体重逐渐下降。 随着治疗的进展，减肥速度加快。 到第 12 周，研究显示 BMI 呈持续下降趋 势，此时平均体重比初始体重减少约 8%。 大约在第 24 周，当体重百分比变化达到约 12-15% 时， 最初的下降开始趋于平稳，速度更平缓 。在此阶段，当与健康饮食和定期锻炼相结合 时，替尔泊肽的效果是显而易见的。到这段时间结束时，患者很可能已经实现了很大一部分目标，为长期减肥奠定了基础。 点击关注，追踪最新GLP-1资讯 ▍ 可能影响替尔泊肽起效时间的因素 新陈代谢 脂肪肝、糖尿病等疾病会使减肥变得更加复杂，因为已经存在一定程度的代谢功能障碍。这些疾病往往伴有更严重的胰岛素抵抗，因此治疗起 来可能更困难或需 ...

自前任总经理霍衍思（Jens Hoeyer）离任以来，该职务由灵北中国区战略财务、商业及合作伙伴关系副总裁杨韶华临时代理。 张一帆上任后，将全面负责灵北在中国大陆及香港地区的业务。杨韶华将继续担任其原有的副总裁职务，聚焦战略财务、业务发展及合作关系 等关键工作。 组织公告, 北京, 2025年6月11日 / Organization Announcement, Beijing, June 110, 2025 (Please scroll down for English version) 组织公告:欢迎张一帆先生担任灵北中国（内地与香港）新任总经理 亲爱的同事们: 整理 | GLP1减重宝典内容团队 今日，灵北全球高级副总裁兼亚太及巴西地区负责人戴麓然（Lorena Di Carlo）宣布，张一帆将于2025年7月1日正式加入灵北中国，出任总经 理一职。 请我们一起祝贺一帆开启新篇章,并欢迎他加入灵北大家庭! 顺致敬意, 戴麗然 灵北全球高级副总裁、亚太及巴西负责人 我很高兴地宣布,张一帆先生将于2025年7月1日正式加入灵北中国（内地与香港）,担任新任总经理。 —帆拥有16年的全球制药行业经验、包括在诺和诺 ...

Core Viewpoint - The article discusses the implications of pausing the use of semaglutide and provides guidance on how to do so safely while maintaining weight management and health benefits [2]. Summary by Sections Timeline: What Happens After Injecting Semaglutide - 1-2 hours: The drug begins to be absorbed into the bloodstream after subcutaneous injection [6]. - 24-48 hours: Peak concentration in the blood is reached, actively binding to GLP-1 receptors [7]. - 1-2 weeks: Initial noticeable effects such as reduced appetite and improved blood sugar regulation may begin [8]. - 4-5 weeks: Steady-state levels are achieved, leading to more pronounced appetite suppression and accelerated weight loss [9]. Best Way to Pause Medication - It is recommended to start with the lowest dose and gradually increase it over months to minimize potential side effects. Sudden discontinuation does not typically cause withdrawal symptoms [10]. - Gradually reducing the dose is advised to mitigate increased hunger that may occur after stopping the medication [12]. - Adjusting injection intervals can help manage the pause: minimum 2 days between injections or less than 12 days for extending the cycle [12]. Effects After Stopping Medication - A 2021 clinical trial showed that participants lost an average of 10.6% of their weight during treatment, but those switched to a placebo regained an average of 6.9% of their weight [13]. - An observational study indicated that 18% of patients regained their lost weight after one year off the medication, while 26% regained more than 25% of their lost weight [13]. Importance of Continuing Medication - The STEP 5 trial demonstrated that continuous use of semaglutide for 2 years resulted in a weight loss of 15.2% compared to placebo [16]. - The SELECT trial showed that patients maintained an average weight loss of about 10% over 4 years, emphasizing the chronic nature of obesity and the need for long-term management [16]. Obesity as a Chronic Disease - Recent studies confirm obesity as a chronic disease, with 76.8% of patients and 94.6% of doctors agreeing on its classification [17]. - Obesity leads to various health issues, increasing the risk of type 2 diabetes and cardiovascular diseases, necessitating its inclusion in chronic disease management [17]. Weight Loss and Chronic Complications - Weight loss of 5% can improve hypertension and blood sugar levels, while a 10-15% reduction significantly lowers the risk of cardiovascular diseases and other complications [19]. - Overall, weight loss interventions can substantially reduce the risk of chronic complications and improve health outcomes for obese patients [19].